Lv1
15 积分 2021-03-04 加入
Discovery of STAT3 Inhibitors: Recent Advances and Future Perspectives
6个月前
已完结
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies
6个月前
已完结
RAS degraders: The new frontier for RAS-driven cancers
6个月前
已完结
Structural analysis of the macrocyclic inhibitor BI-4020 binding to EGFR kinase
7个月前
已完结
Structural elements that enable specificity for mutant EGFR kinase domains with next-generation small-molecule inhibitors
7个月前
已完结
Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises
7个月前
已完结
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020-2023)
7个月前
已完结
Evidence of nigericin as a potential therapeutic candidate for cancers: A review
8个月前
已完结
Continuous evolution of compact protein degradation tags regulated by selective molecular glues
8个月前
已完结
Structural rationalization of GSPT1 and IKZF1 degradation by thalidomide molecular glue derivatives
8个月前
已完结
皖公网安备34019202002308
